Drug intelligence / Profile preview

thiazolidinediones-C

Development stage: Preclinical
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

Thiazolidinediones-C is a novel synthetic compound belonging to a series of thiazolidine-2,4-diones. It features an amide linkage between a central aryl ring and a hydrophobic tail. Designed and synthesized for anti-diabetic activity, it has demonstrated significant in-vivo pharmacological effects, including blood glucose and triglyceride lowering, comparable to the standard anti-diabetic drug pioglitazone. Computational studies suggest its mechanism involves interaction with peroxisome proliferator-activated receptor gamma (PPARγ).

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)FFAR1 (Free fatty acid receptor 1)

Beyond the preview

Go deeper on thiazolidinediones-C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thiazolidinediones-C.

Explore the full profile